← Back to Search

Virus Therapy

Fluad vaccine for Influenza

Phase 4
Waitlist Available
Led By Richard B Kennedy
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 8, day 28
Awards & highlights

Study Summary

This trial is investigating why the elderly have a weaker immune response to flu vaccines, with the hope of developing more effective vaccines in the future.

Eligible Conditions
  • Influenza

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hemagglutination Inhibition Ab Titer
Innate Cell IFNa2a Production
Innate Cell miRNA Expression
+4 more
Secondary outcome measures
CD4/CD8 Ratio
CMV Serostatus
Innate Cell Phenotype
+2 more

Trial Design

2Treatment groups
Active Control
Group I: Fluad vaccineActive Control1 Intervention
Subjects receive a single dose of the Fluad influenza vaccine.
Group II: Fluzone vaccineActive Control1 Intervention
Subjects receive a single dose of the Fluzone High-Dose influenza vaccine.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,209 Previous Clinical Trials
3,766,893 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,269 Previous Clinical Trials
5,481,228 Total Patients Enrolled
Richard B KennedyPrincipal InvestigatorMayo Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~37 spots leftby Apr 2025